Effects of Plasmapheresis on Aging Biomarkers

Aging Clinical Trial

Official title:

Studie Vlivu darování krevní Plazmy - Plasmapheresis. Study of the Plasma Donation Effect - Plasmapheresis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05004220
• Other study ID #: 202103 P07
• Status: Completed
• Start date: April 6, 2021
• Est. completion date: February 10, 2023

Study information

• Verified date: September 2023
• Source: Charles University, Czech Republic
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of the study is to evaluate the effect of plasmapheresis (repeated plasma withdrawals) on selected health indicators (hematological, biochemical, immunological and indicators of biological age) of plasma donors.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: February 10, 2023
• Est. primary completion date: August 16, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Generally healthy volunteer subjects age 40 - 60

2. 50:50 man and woman

Exclusion Criteria:

1. Subjects excluded from plasma donation protocols (serious illness, infection, etc)

2. Subjects undergoing stronger anti-aging interventions

Related Conditions & MeSH terms

• Aging
• Plasmapheresis

Intervention

Procedure:
• Plasmapheresis
Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor.

Locations

Country	Name	City	State
Czechia	Charles University, Medical Faculty in Hradec Kralove	Hradec Králové

Sponsors (5)

Lead Sponsor	Collaborator
Charles University, Czech Republic	AGECURVE LIMITED, Clock Foundation, Longevitytech.fund a.s., University Hospital Hradec Kralove

Country where clinical trial is conducted

Czechia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Significant change of biological age according to epigenetic clock after 8 plasmaphereses	Significant change of the epigenetic age of the plasma donors after 8 cycles of plasmapheresis conducted or a slower increase of the biological age throughout the study than the increase of the chronological age.	Through study completion, an average of 8 months
Secondary	Significant change of biological age according to epigenetic clock after 8 plasmaphereses	Significant change of the epigenetic age of the plasma donors after 4 cycles of plasmapheresis conducted or a slower increase of the biological age throughout the study than the increase of the chronological age.	Through study completion, an average of 8 months
Secondary	Significant change of the proteomic profile after 8 plasmaphereses	Proteomic analysis showing signs of a rejuvenated proteostasis in the plasma donors after 8 cycles of plasmapheresis.	Through study completion, an average of 8 months
Secondary	Significant change of the proteomic profile after 4 plasmaphereses	Proteomic analysis showing signs of a rejuvenated proteostasis in the plasma donors after 8 cycles of plasmapheresis.	Through study completion, an average of 8 months
Secondary	Significant change of the biological age according to a blood biochemistry clock after 8 plasmaphereses	Blood biochemistry clock showing phenotype of a younger individual in the plasma donors after 8 cycles of plasmapheresis.	Through study completion, an average of 8 months
Secondary	Significant change of the biological age according to a blood biochemistry clock after 4 plasmaphereses	Blood biochemistry clock showing phenotype of a younger individual in the plasma donors after 8 cycles of plasmapheresis.	Through study completion, an average of 8 months